[1] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2022年版). 中华肝脏病杂志,2022,30(12):1309-1331.
[2] Richter GM , Palmaz JC , Nldge G ,et al. The transjugular intrahepatic portosystemic stent-shunt. A new nonsurgical percutaneous method.Der Radiologe, 1989, 29(8):406-411.
[3] Envelope RDFP , Bosch J , Garcia-Tsao G ,et al. Baveno VII – Renewing consensus in portal hypertension.J Hepatol, 2022, 76( 4):959-974.
[4] 曹家伟,丁鹏绪,段峰,等. 中国门静脉高压经颈静脉肝内门体分流术临床实践指南(2019年版).临床肝胆病杂志,2019,35(12):2694-2699.
[5] 张露,范志芳,刘殿武,等.1990-2016年中国乙型肝炎引起的肝硬化及其他慢性肝病疾病负担变化趋势分析.中华流行病学杂志, 2020, 41(2):5.
[6] Durand F, Levitsky J, Cauchy F, et al. Age and Liver Transplantation.J Hepatol, 2018,70(4):745-758.
[7] Carrier P , Debette-Gratien M , Jérémie Jacques,et al.Cirrhotic patients and older people.World Journal of Hepatology, 2019, 11(9):678-688.DOI:10.4254/wjh.v11.i9.678.
[8] Cesari M, Frigo AC, Tonon M, et al. Cardiovascular predictors of death in patients with cirrhosis.Hepatology, 2018, 68(1):215-223..
[9] Casadaban LC, Parvinian A, Minocha J, et al. Clearing the Confusion over Hepatic Encephalopathy After TIPS Creation: Incidence, Prognostic Factors, and Clinical Outcomes. Dig Dis Sci,2015,60(4):1059-1066.
[10] Ascha M, Abuqayyas S, Hanouneh I, et al. Predictors of mortality after transjugular portosystemic shunt. World J Hepatol. 2016 Apr 18;8(11):520-529.
[11] Bettinger D , Thimme R , Schulthei M. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection. Curr Opin Gastroenterol. 2022, 38(3):221-229.
[12] Syed MI, Karsan H, Ferral H, et al. Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension.World J Hepatol, 2012, 4(2):35-42.
[13] 黄山,姚欣,周昊,等.经颈静脉肝内门体分流术治疗老年肝硬化门静脉高压病人的长期疗效分析.实用老年医学, 2021, 35(7):5.
[14] Lena S , Marie S , Tergast TL ,et al. Safety and feasibility of transjugular intrahepatic portosystemic shunt in elderly patients with liver cirrhosis and refractory ascites.PloS one, 2020, 15(6):e0235199.
[15] Suraweera D, Jimenez M, Viramontes M, et al. Age-related Morbidity and Mortality After Transjugular Intrahepatic Portosystemic Shunts. J Clin Gastroenterol, 2017, 51(4):360-363..
[16] Bisht RU , Liu MC , Koblinski JE ,et al. Is 70 the new 50? Complications and outcomes of transjugular intrahepatic portosystemic shunt in older versus younger patients.Abdom Radiol (NY), 2021 46(6):2789-2794.
[17] Nael S, Katherine RM, Michael D, et al. Older age is associated with increased early mortality after transjugular intrahepatic portosystemic shunt. .Ann Hepatol, 2016, 15: 215-221.
[18] Pan JJ, Chen C, Caridi JG, et al.Factors Predicting Survival after Transjugular Intrahepatic Portosystemic Shunt Creation: 15 Years' Experience from a Single Tertiary Medical Center. J Vasc Interv Radiol. 2008, 19(11):1576-1581.
[19] Russo A. Outcomes After Transjugular Intrahepatic Portosystemic Shunt in Cirrhotic Patients 70 Years and Older.J Clin Med, 2020, 9(2):381.
[20] Zohaib A, Umer F, Syeda FA,et al. Transjugular Intrahepatic Portosystemic Shunt Outcomes in the Elderly Population: A Systematic Review and Meta-Analysis .Gastroenterology Res, 2022, 15: 325-333.
[21] Francesco V, Ciro C, Vincenza C, et al. Mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis: A validated prediction model. .Hepatology, 2023, 77: 476-488. |
